Skip to main navigation Skip to search Skip to main content

A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date06/28/16 → 06/27/23

Funding

  • FKD Therapies Oy: $134,533.20